Agronomics Limited Announces All G Co Update
All G, an Agronomics portfolio company, has become the first company globally to receive regulatory clearance for selling recombinant bovine lactoferrin in China. The company uses precision fermentation to develop animal-free proteins for functional foods and nutrition. This approval allows All G to generate initial revenue streams before its Series B funding round, with product launch planned for 2025. All G aims to produce lactoferrin at or below price parity compared to conventional methods. The company has raised AU$ 45 million to date, with Agronomics investing AU$ 15 million, currently valued at £7.9 million as of June 2024.
All G, un'azienda del portafoglio di Agronomics, è diventata la prima azienda al mondo a ricevere l'approvazione regolatoria per la vendita di lattoferrina bovina ricombinante in Cina. L'azienda utilizza la fermentazione di precisione per sviluppare proteine senza origine animale per alimenti funzionali e nutrizione. Questa approvazione consente ad All G di generare flussi di entrate iniziali prima del suo round di finanziamento di Serie B, con il lancio del prodotto previsto per il 2025. All G punta a produrre lattoferrina a un prezzo pari o inferiore rispetto ai metodi convenzionali. L'azienda ha raccolto 45 milioni di dollari australiani fino ad oggi, con Agronomics che ha investito 15 milioni di dollari australiani, attualmente valutata 7,9 milioni di sterline a giugno 2024.
All G, una empresa del portafolio de Agronomics, se ha convertido en la primera empresa a nivel mundial en recibir la autorización regulatoria para vender lactoferrina bovina recombinante en China. La compañía utiliza fermentación de precisión para desarrollar proteínas libres de animales para alimentos funcionales y nutrición. Esta aprobación permite a All G generar flujos de ingresos iniciales antes de su ronda de financiación de Serie B, con el lanzamiento del producto previsto para 2025. All G tiene como objetivo producir lactoferrina a un precio equivalente o inferior en comparación con los métodos convencionales. La empresa ha recaudado 45 millones de dólares australianos hasta la fecha, con Agronomics invirtiendo 15 millones de dólares australianos, actualmente valorada en 7,9 millones de libras en junio de 2024.
All G는 Agronomics 포트폴리오 회사로, 중국에서 재조합 소 락토페린 판매를 위한 규제 승인 을 받은 세계 최초의 회사가 되었습니다. 이 회사는 정밀 발효를 사용하여 동물 없는 단백질을 개발하여 기능성 식품과 영양소에 사용합니다. 이 승인은 All G가 시리즈 B 자금 조달 라운드 전에 초기 수익 흐름을 생성할 수 있게 해주며, 제품 출시는 2025년으로 계획되고 있습니다. All G는 기존 방법에 비해 가격 평형점에서 혹은 그 이하로 락토페린을 생산하는 것을 목표로 하고 있습니다. 이 회사는 현재까지 4500만 호주 달러를 모금했으며, Agronomics가 1500만 호주 달러를 투자하여, 2024년 6월 기준으로 790만 파운드의 가치가 있습니다.
All G, une entreprise du portefeuille d'Agronomics, est devenue la première entreprise au monde à recevoir l'autorisation réglementaire de vendre de la lactoferrine bovine recombinante en Chine. L'entreprise utilise la fermentation de précision pour développer des protéines sans origine animale pour des aliments fonctionnels et la nutrition. Cette approbation permet à All G de générer des flux de revenus initiaux avant son tour de financement de série B, avec un lancement de produit prévu pour 2025. All G vise à produire de la lactoferrine à un prix égal ou inférieur par rapport aux méthodes conventionnelles. L'entreprise a levé 45 millions de dollars australiens à ce jour, avec Agronomics investissant 15 millions de dollars australiens, actuellement évaluée à 7,9 millions de livres sterling en juin 2024.
All G, ein Unternehmen aus dem Agronomics-Portfolio, ist das erste Unternehmen weltweit, das die regulatorische Genehmigung zum Verkauf von rekombinanter boviner Laktotransferrin in China erhalten hat. Das Unternehmen nutzt Präzisionsfermentation, um tierfreie Proteine für funktionale Nahrungsmittel und Ernährung zu entwickeln. Diese Genehmigung ermöglicht es All G, vor der Series-B-Finanzierungsrunde erste Einnahmequellen zu generieren, wobei der Produktstart für 2025 geplant ist. All G zielt darauf ab, Laktotransferrin zu einem Preis zu produzieren, der dem konventionellen Verfahren entspricht oder darunter liegt. Bisher hat das Unternehmen 45 Millionen AUD gesammelt, wobei Agronomics 15 Millionen AUD investiert hat und die Bewertung im Juni 2024 bei 7,9 Millionen Pfund liegt.
- First company worldwide to receive regulatory approval for recombinant bovine lactoferrin in China
- Entry into China's market, one of the largest lactoferrin consumers globally
- Expected positive margins with production at or below price parity
- Initial revenue generation ahead of Series B funding round
- Product launch not until 2025
- Still pending regulatory approvals in US, Australia, New Zealand, and Japan
- Additional approval needed for infant formula use in China
All G Receives Approval for Sale of Recombinant Bovine Lactoferrin in China
DOUGLAS, ISLE OF MAN / ACCESSWIRE / November 27, 2024 / Agronomics (LSE:ANIC), a leading listed company in the field of cellular agriculture, is delighted to announce that its portfolio company, All G Co Holdings Pty Limited ("All G"), is the first company in the world to receive regulatory clearance for the sale of recombinant bovine lactoferrin in China.
All G is an Australian-based biotechnology company at the forefront of using precision fermentation to develop high-value, animal-free proteins for use in a variety of markets - ranging from functional foods, medical nutrition and infant nutrition.
Lactoferrin, a whey protein found in human and cow milk, is highly sought-after for its numerous functional benefits, including enhancing gut function, iron absorption and providing antimicrobial and anti-inflammatory benefits. However, due to its low concentration in cow's milk, it is expensive to produce and yields only limited quantities, creating a major opportunity for alternative protein producers.
China represents one of the largest consumers of lactoferrin globally, driven by a growing demand for functional foods and health-conscious consumers. The approval allows for the sale of All G's product into a specific target market which will be disclosed closer to the time of market entry. The company is simultaneously progressing with regulatory approval for the use of its lactoferrin in infant formula, which is expected in 2025.
This approval is significant for All G, as it will allow the company to bring in initial revenue streams in advance of its Series B fund raise. Revenues are projected to be at positive margins as All G aims to produce at or below price parity compared with conventionally produced lactoferrin. All G intends to release its first lactoferrin product in 2025 and plans to receive approval for its products in the US, Australia, New Zealand, and Japan.
All G's regulatory approval in China comes after only three years of operations. To date, All G has raised AU
Commenting on the announcement, Jan Pacas, All G CEO, said: "This approval is a great moment for All G as we lead the way in precision fermentation technology. Lactoferrin is one of the most valuable and functional proteins in the world. Our technology unlocks its potential, and this is just the beginning - our recombinant human lactoferrin is progressing rapidly, with many other products in the pipeline."
Jim Mellon, Agronomics' Executive Chair, added: "Today's announcement is another testament to the strength of the Agronomics portfolio. All G is one of the leading technology companies developing animal-free proteins and achieving regulatory approval for Lactoferrin in China - the world's largest market - is an exciting step for the industry. More importantly, it provides a platform from which All G can bring other key products to market at competitive prices."
About All G
All G is a Sydney-based biotechnology company that is at the forefront of precision fermentation, developing high-value, animal-free proteins for use in functional foods, medical nutrition and infant nutrition. Founded in 2020 by CEO Jan Pacas, the company has successfully raised AU
About Agronomics
Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.
For further information please contact:
Agronomics Limited | Beaumont Cornish Limited | Canaccord Genuity Limited | Cavendish Securities Plc | Peterhouse Capital Limited | SEC Newgate |
The Company | Nomad | Joint Broker | Joint Broker | Joint Broker | Public Relations |
Jim Mellon Denham Eke | Roland Cornish James Biddle | Andrew Potts Harry Pardoe Alex Aylen (Head of Equities) | Giles Balleny Michael Johnson | Lucy Williams Charles Goodfellow | Bob Huxford Anthony Hughes |
+44 (0) 1624 639396 | +44 (0) 207 628 3396 | +44 (0) 207 523 8000 | +44 (0) 207 397 8900 | +44 (0) 207 469 0936 |
Nominated Adviser
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Agronomics Limited
View the original press release on accesswire.com
FAQ
When will All G launch its lactoferrin product in China?
How much has Agronomics (AGNMF) invested in All G?
What markets is All G seeking regulatory approval for lactoferrin?
What is the total funding raised by All G to date?
